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INTRODUCTION  
INTRODUCTION 
 
 Chronic renal failure (CRF) is associated with increased 
morbidity and mortality. Chronic renal failure affects almost all systems 
of the body and results in various abnormalities. Among the various 
causes, infections and cardiovascular causes contribute towards the 
large proportion of increased morbidity and mortality. 
 
 Cardiac disease is the major cause of death in CRF patients 
accounting for 40% of deaths in international registries. 
 
 In 1997, annual report of US Renal Data System (USRDS) 
revealed that morbidity in patients with CRF is attributed mainly to 
cardiac causes which account for 49% of the cases. 
 
 In the cardiovascular system, left ventricular hypertrophy (LVH) 
is the most frequent finding. The prevalence of left ventricular systolic 
and diastolic dysfunction is less clear. 
 
 Cardiac disease frequently predates the start of dialysis and 
LVH is common in moderate to severe chronic renal failure. 
 
 Echocardiography is one of the non invasive and sensitive tests 
for evaluating various cardiac changes in CRF patients at an early 
stage. Echocardiography should be performed early in the course of 
CRF and may be valuable in the monitoring of therapy of these 
patients. Cardiac dysfunction is the major impediment to rehabilitation. 
 
 Patients in developing countries are managed mainly on 
conservative therapy and therefore, suffer from chronic acidosis, 
malnutrition, anaemia and azotemia. These factors further aggravate 
the cardiac dysfunction in uraemic patients. 
 
 The severe cardiac dysfunction is frequently noted in individuals 
around the time of commencement of dialysis, but there is little 
information on the prevalence and natural history of cardiac function in 
patients with milder degrees of chronic renal failure. 
 
 The present study was aimed at assessing the prevalence of 
systolic and diastolic dysfunction by echocardiography in patients with 
varying degrees of chronic renal failure who had been on conservative 
management. 
 
 Eighty percent to 90% of patients with chronic kidney disease 
experience hypertension during the course of the disease. 
Uncontrolled hypertension accelerates the rate of progression 
regardless of the cause of renal failure. Hence this study has also 
been used to compare the various cardiac changes in hypertensive 
CRF patients with normotensive CRF patients. 
  
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
REVIEW OF LITERATURE 
 
Cardio vascular aspects of chronic renal failure (CRF) 
Background 
 Chronic Kidney disease is a pathophysiologic process with 
multiple etiologies, resulting in the inexorable attrition of nephron 
number and function and frequently leading to end stage renal disease 
(ESRD). 
 
 The definition of CRF requires that the pathophysiologic process 
described above last more than 3 months. A recently widely accepted 
international classification divides CRF into a number of stages 
defined by clinical estimation of the Glomerular filtration rate (GFR). 
 
Table : Stages of chronic kidney disease 
Stage Description 
 
eGFR, ml/min per 
1.73 m2 
 * At increased risk 90 (with CRF risk 
factors) 
1. Kidney damage with normal or 
increased GFR 
90 
2. Kidney damage with mildly 
decreased GFR 
60-89 
3. Moderately decreased GFR 30-59 
4. Severely decreased GFR 15-29 
5. Renal failure/ESRD < 15 (or dialysis) 
 
 For purposes of staging CRF, Current guidelines recommend 
estimating GFR using one of the two equations shown as below. 
 
Recommended equation for Estimation of Glomerular Filtration 
Rate from Laboratory – Validated Plasma Creatinine 
Concentration (Pcr) 
 
 Equation from the Modification of Diet in Renal Disease 
Study (MDRD) 
Estimated GFR (ml/min per 1.73 m2) 
= 1.86 x (Pcr)-1.154 x (age) – 0.203 
Multiply by 0.742 for women  
Multiply by 1.21 for blacks 
 
 Cockcroft – Gault equation 
Estimated Creatinine clearance (ml/min) 
= (140-age) x body weight (kg) 
  72 x Pcr (mg/dl) 
Multiply by 0.85 for women 
 
 A common definition for CRF stipulates an eGFR of less than 60 
ml/min/1.73m2 or the presence of albuminuria, defined as an albumin 
to creatinine ratio greater than 30 mg/gm on a spot urine sample. 
Although with normative aging (age 20 to 80), the eGFR declines from 
about 130 to 60 ml/min/1.73 m2, a variety of pathobiological processes 
appear to begin when the eGFR drops below 60 ml/min/1.73m2. 
 
 Most of the cardiovascular derangements occur below an eGFR 
of 60ml/min/1.73m2, which roughly corresponds to a serum creatinine 
(Cr) greater than 1.5 mg/dl in the general population. 
 
Approximate prevalence (%) of cardiovascular disease in the 
general population and in patients with chronic kidney disease 
 
Population Coronary 
Artery 
Disease 
(Symptomatic) 
Left ventricular 
hypertrophy 
(Echocardiogram) 
Cardiac failure 
(Symptomatic) 
General 
population 
5-12 20 5 
Predialysis NA 25-50 NA 
Hemodialysis 42 75 40 
Peritoneal 
analysis 
40 75 40 
Renal 
transplantation 
15 50 10 
 
*NA not available 
 
 Most clinical consequences of cardiac disease result from 
cardiomyopathy (or) ischemic heart disease. Cardiomyopathy may 
manifest as an enlarged, dilated left ventricle (LV) with systolic 
dysfunction (or) as a hypertrophic ventricle with diastolic dysfunction, 
with or without myocardial ischemia. 
 
 It has also become evident that the structure of large arteries 
can be altered, not only by atherogenesis, but also by arteriosclerosis. 
Intramural vascular remodeling occurs as a consequence of sustained 
hemodynamic overload, with an increase in vessel stiffness and 
diameter. 
 
 There is a persistent and complex interplay of destructive 
vascular events and myocyte dysfunction that, if unrecognized, 
ultimately results in cardiac failure and death. 
 
 Arteriosclerosis contributes directly to ischemic symptoms, LV 
hypertrophy and systolic dysfunction by increasing cardiac workload. 
LV hypertrophy occurs in most of the severe renal failure cases and 
there is diastolic dysfunction with or without normal systolic function. 
 
 Cardiac disease can also result from the development of 
valvular heart disease. Most valvular lesions observed in patients with 
CRF are acquired and develop from dystrophic calcifications of the 
valvular annulus and leaflets, particularly the aortic and mitral valves. 
Such calcification is now known to be present far more frequently than 
previously recognized, with a prevalence of upto 55%, for the aortic 
valves and 39% for the mitral valves (Foley RN, Parfrey PS et al, Am J 
Kidney Dis, 1998 and London GM et al J Am Soc Nephrol, 2000). 
 
 LV Hypertrophy is already evident in 40% of patients with 
moderate renal insufficiency and in 75% of those commencing dialysis 
(Levin A, Singer J, Thompson CR, et al, 1995). Both forms of LV 
hypertrophy (concentric and eccentric) are associated with an 
increased mortality risk in CRF patients. 
 
 Associated risk factors, including hypertension, diabetes, 
tobacco – use and anemia predispose to the much more rapid 
development of symptomatic cardiomyopathy. (Levin A, Thompson 
CR, 1999). 
 
 Such patients display a higher incidence of cardiovascular 
abnormalities at an earlier stage of CRF and at a younger age, often 
becoming symptomatic or exhibiting significant morbidity well before 
reaching end stage kidney function. 
 
PATHOLOGY AND PATHOPHYSIOLOGY 
 
LV Hypertrophy is an adaptive process that occurs in response 
to a long term increase in myocardial work caused by LV pressure or 
volume overload; it results from the interactions among mechanical 
stimuli, locally generated growth factors and vasoactive substances. 
 
LV tensile wall stress (σ), according to the law of Laplace, 
relates directly to the intraventricular pressure (P) generated and to the 
internal radius (r) of the ventricular cavity. It is inversely proportional to 
the ventricular wall thickness (θ). 
σ = Pr / 2θ 
 
Therefore, the wall tension at any given pressure increases with 
the radius and vice versa. Conversely, as pressure (or) cavity volume 
(or both) is increased, there is an increase in wall thickness which 
reduces the systolic tension (and hence oxygen consumption) that 
must be developed by each myocyte. It is this wall remodeling that 
results in LV hypertrophy. The initial effects of LV hypertrophy are 
beneficial. 
 
Eventually, however LV hypertrophy becomes maladaptive, with 
a sustained imbalance between energy expenditure and production, 
resulting in a chronic energy deficit and myocyte death. Within the 
myocardium, overstretching of papillary muscles is coupled with 
oxidant stress, apoptosis, architectural rearrangement of myocytes, 
and impairment in force development of myocardium (Cheng W, Li B, 
Kajstura) et al; Stretch induced programmed myocyte cell death, 
1995). 
 
There is also evidence that abnormal expression of proto-
oncogenes promotes the development of, particularly, fibroblasts, with 
an increase in extracellular collagen matrix and hence the 
development of myocardial fibrosis. 
 
The consequences of these alterations are electrophysiologic 
abnormalities and maintenance of systolic efficiency at the expense of 
impaired diastolic filling. Arrhythmias are caused partly by conduction 
aberrations secondary to fibrosis and partly by prolongation of the 
action potential due to a slower reuptake of calcium by the 
sarcoplasmic reticulum. The latter, together with fibrotic change and 
increased LV wall stiffness, contributes substantially to abnormal 
diastolic function. 
 
As a result, the geometry of the heart changes from concentric 
LV hypertrophy with normal LV volumes to eccentric LV hypertrophy 
with dilatation, the end stage of this tendency being severe LV 
dilatation with systolic dysfunction. 
 
Eventually, in conditions of chronic and sustained overload, the 
deleterious effects of hypertrophy, increased LV chamber pressure, 
and fibrosis dominate, leading to the development of cardiomyopathy 
and LV failure (Katz AM : Ann Intern Med, 1994). 
 
Morphology of ventricular myocytes in cardiac hypertrophy and 
failure 
 
 
 
 
 
 
 
Functional Abnormalities 
 
 Assessment of LV functional abnormalities in patients with CRF 
is often difficult.  
 
Absence of symptoms does not imply intact functional reserve 
regardless of the stage of disease. The difficulties can be encountered 
when trying to distinguish clinically between systolic and diastolic 
dysfunction since multiple pathologic conditions are frequently present 
simultaneously, although usually one particular condition predominates 
in a clinical context. 
 
Diastolic Dysfunction 
 The degree of disturbance is probably more than that observed 
in patients with hypertensive heart disease but milder than in those 
with hypertrophic cardiomyopathy. The abnormal ventricular filling in 
uremia results from increased LV stiffness caused by intramyocardial 
fibrosis and associated delayed relaxation. By virtue of an increase in 
LV stiffness, small changes in volume result in large changes in LV 
pressure, predisposing to symptomatic pulmonary edema. The reverse 
is also true : volume depletion results in a large fall in LV pressure with 
symptomatic hypotension and  hemodynamic instability. (Ritz E, 
Rambausek M, et al, 1990) This is often the presenting feature of 
diastolic dysfunction. 
 
Systolic Dysfunction 
 Resting systolic function is usually normal or even increased in 
patients with advanced renal disease in the absence of antecedent 
cardiac disease. However, decreased systolic function is frequently 
observed in patients in whom cardiac disease was present before the 
onset of dialysis therapy and in patients who have experienced 
prolonged and marked hemodynamic overload. Approximately 15% of 
patients have systolic dysfunction by the time they start dialysis. (Foley 
RN, Parfrey PS et al, 1995) Diminished myocardial contractility may 
also be a result of overload cardiomyopathy, in which the myocardium 
relies on starling forces to maintain a normal output. The 
manifestations of cardiomyopathy has a substantially worse prognosis 
than that for either concentric LV hypertrophy or LV dilatation with 
normal systolic function. 
 
 In dialysis patients, systolic dysfunction is strongly associated 
with the presence of ischemic heart disease or sustained 
biomechanical stress or both. However, it can also be a reversible 
manifestation of severe uraemia, abating when the uremic 
environment is removed. Uremic serum has been found to reduce the 
force of contraction of cultured myocytes in a concentration – 
dependent manner. (Weusenee D Low – Friedrich I et al : Invitro 
approach to “Uremic Cardiomyopathy”, Nephron, - 1993). 
 
 Renal transplantation has also been shown to normalize systolic 
function in dialysis patients with systolic dysfunction and subsequently 
to reduce but not normalize LV mass index. 
 
Symptomatic Heart Failure 
 LV failure is a clinical condition that can be defined as the 
inability of the heart to maintain sufficient output to meet metabolic 
demands at rest, or the ability to maintain such demands only at the 
expense of a sufficiently raised venous pressure to result in pulmonary 
edema. If left untreated, myocardial hypertrophy can be viewed as an 
early milestone in the clinical course of cardiac failure. 
 
 In a Canadian Cohort study, 275 patients had serial 
echocardiograms on starting dialysis and after 1 year of dialysis 
therapy. An increase in LV mass index was an independent risk factor 
for the development of subsequent heart failure (hazard ratio, 1.3 per 
each 20 g/m2 increase), as was a reduction in fractional shortening 
(hazard ratio, 1.43 per 5% decrease). 
 
 Both LV hypertrophy and LV dilatation will ultimately progress to 
dilated cardiomyopathy if pressure and volume overload are not 
appropriately managed. Conversely, there is some evidence of a 
reduction in LV hypertrophy and possibly in mortality if due attention is 
paid to these risk factors. 
 
 In cardiac failure, ventricular output is maintained at the expense 
of numerous mechanisms. These include an increase in both end 
diastolic fiber length and end diastolic volume (i.e through the Frank – 
Starling mechanism), increased sympathetic activity, enhanced 
secretion of regulatory hormones (e.g. angiotension II, Arginine 
vasopressin, vasoactive endothelial hormones, brain and atrial 
natriuretic peptide) and the presence of ouabain – like substances 
which, through impairment of the sodium – potassium pump (Na+, K+ 
ATPase), result in enhanced contractility, albeit at the expense of 
impaired relaxation. 
 
 In a circuit already coping with an elevated LV volume and 
pressure this can easily result, as previously seen, in a raised 
pulmonary capillary pressure. The clinical presentation then is one of 
symptomatic heart failure, with dyspnoea and pulmonary venous 
congestion, ultimately resulting in acute pulmonary edema. 
 
 This end stage clinical manifestation of cardiac disease may 
result from systolic failure, usually caused by dilated cardiomyopathy 
or ischemia or both, (or) from diastolic dysfunction in association with 
LV hypertrophy. The latter is almost as frequent as a cause of 
recurrent or persistent heart failure in dialysis patients as is dilated 
cardiomyopathy (Pafrey PS, Harnett JD et al, 1998). 
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Haemodynamics of HT in CRF 
Hypertension is both a cause and complication of renal failure. It 
is one of the most serious complications of CRF. 
 
 It is the major risk factor for CCF, CVA, CAD. After the 
introduction of recombinant human erythropoietin, anaemia is 
corrected and aggravation of hypertension occurs, so previously 
normotensive patients may become hypertensive. 
 
 Clinical trials and epidemiologic studies indicate that 
hypertension is a major risk factor for progressive kidney disease. 
 
Evaluation of subjects screened in a multiple risk factor 
intervention trial who were monitored over a 16 year period showed 
that  
• Higher the blood pressure was a strong and independent 
risk factor for the development of ESRD and 
• The relative risk for ESRD increased with rising systolic 
blood pressure independent of diastolic blood pressure. 
 
Analysis of National Health and Nutrition Evaluation survey III 
Data suggests that adequate blood pressure control is achieved in 
only 11% of patients with hypercreatininemia (serum creatinine > 1.5 
mg/dl). 
 
Documentation of blood pressure is essential in the assessment 
of CRF because this parameter is strongly associated with kidney 
disease progression and cardio vascular mortality. 
 The goal blood pressure for patients with CRF is 120 to 139 mm 
of Hg systolic and 70 to 85 mm of Hg diastolic, depending on the 
disease type. 
 
The results from nine independent clinical trials five in patients 
with diabetic nephropathy and four in patients with non diabetic 
nephropathy indicate that mean rate of decline in GFR is directly 
associated with level of mean systolic blood pressure (SBP) during the 
trial.  
 
The rate of decline in GFR in patients with nephropathy even at 
normal systolic blood pressure, is more than twice that associated with 
aging in normal individuals. 
 
 
 
Absence of hypertension may signify the presence of a salt 
wasting form of renal diseases such as medullary cystic disease, 
chronic tubulo interstitial disease, or papillary necrosis and ongoing 
antihypertensive therapy, volume depletion due to gastrointestinal 
causes (or) diuretic therapy, or reduced cardiac index. 
 
Since volume overload is the major cause of hypertension in 
uremia, the normotensive state can often be restored by appropriate 
(not overzealous) use of salt restriction and natriuretic drugs or ultra 
filtration in the dialysis setting. Nevertheless, because of 
hyperreninemia and other disturbances in renal vasoconstrictors and 
vasodilators, some patients remain hypertensive despite vigorous salt 
and water restriction and ultrafiltration. Rarely, such patients may 
develop accelerated (or) malignant hypertension. 
 
Ischemic Cardiovascular disease 
 CRF at all stages constitutes a major risk factor for ischemic 
cardiovascular disease, including occlusive coronary heart, cerebro 
vascular and peripheral vascular diseases. Increased prevalence of 
coronary heart disease in CRF derives from both traditional (‘’ classic) 
and CRF- related non traditional risk factors. 
 
 The traditional risk factors include hypertension, hypervolemia, 
dyslipidemia, sympathetic over activity and hyperhomocysteinemia.  
 
 The CKD related risks include anaemia, hyperphosphatemia, 
hyperparathyroidism and a state of “micro inflammation” that can be 
found at all stages of CRF but is undoubtedly aggravated by dialysis.  
 
 The inflammatory state elicits a rise in acute phase reactants 
such as IL-6 and CRP, which contribute to the coronary occlusive 
process and are predictors of cardiovascular disease risk. Other 
abnormalities augment myocardial ischemia. These include reduced 
myocardial tolerance to ischemia due to left ventricular hypertrophy 
and microvascular disease. 
 
 Nitric oxide is an important mediator for vascular dilatation. Its 
availability in CRF is decreased because of increased concentrations 
of asymmetric dimethyl – l – arginine, even at early stages of CRF and 
also because nitric oxide is scavenged by reactive O2 species. In 
addition, coronary arteriolar hypertrophy / hyperplasia limits 
vasodilatory capacity. 
 
Pericarditis 
 With the advent of early initiation of renal replacement therapy, 
pericarditis is now observed more often in underdialysed patients than 
in predialysis CRF patients. Pericardial pain with respiratory 
accentuation, accompanied by a friction rub, are the hall marks of 
uremic pericarditis. 
 
 The finding of a multicomponent friction rub strongly supports 
the diagnosis. Classic electro cardiographic abnormalities include PR 
interval depression and diffuse ST segment elevation. Pericarditis may 
be accompanied by the accumulation of pericardial fluid that is readily 
detected by echocardiography and that sometimes leads to cardiac 
tamponade. Pericardial fluid in uremic pericarditis is more often 
hemorrhagic than in viral pericarditis. 
 
Potentially modifiable cardiovascular risk factors in chronic 
kidney disease - Identified by Cohort studies 
 
Predialysis Renal 
transplant 
Dialysis  
 
LVH LVH CHF IHD LVH CHF IHD Death 
Anemia + + + - + + - + 
Hypertension + + + + + + + - 
Hyperlipidemia - - - + - - - - 
Smoking - - - + - + + + 
Hypoalbuminemia - - - + - + - + 
C-reactive protein - - - - - - - + 
Homocysteine - - - - - - - + 
Divalent ion 
abnormalities 
- - - - - - - + 
 
CHF – Congestive heart failure  
IHD – Ischemic heart disease 
LVH – Left ventricular hypertrophy 
  
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY  
 
AIM OF THE STUDY 
 
• To evaluate the cardiac abnormalities in patients of chronic renal 
failure by echocardiography. 
 
• To assess the prevalence of systolic and diastolic dysfunction in 
patients with varying degrees of chronic renal failure on 
conservative management. 
 
• To compare the various cardiac changes in hypertensive CRF 
patients with normotensive CRF patients. 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS  
 
MATERIALS AND METHODS 
 
Setting   : Chronic Renal Failure patients  
admitted in Madurai Medical College, 
Government Hospital. 
 
Collaborating Departments: Department of Nephrology, 
     Madurai Medical College Hospital, 
     Madurai. 
 
     Department of Cardiology, 
     Madurai Medical College Hospital, 
     Madurai. 
 
Design of Study  : Prevalence and Comparative study 
 
Period of Study  : 01-03-2005 to 28-02-2006 
 
Sample Size  : 120 
 
 
Selection of Study Subjects : 
The study population consists of chronic renal failure patients 
admitted in this hospital for the period from March 2005 to February 
2006. They are basically divided into three groups according to 
Glomerular Filtration rate calculated by using one of the standard 
equations, Cockroft – Gault equation and each group consisted of 
thirty patients. Of the thirty patients in each group, twenty patients 
were with hypertension and ten patients were without hypertension 
and not receiving any antihypertensive drugs.  
 
 The GFR was calculated by measuring creatinine clearance by 
using Cockroft Gault equation. 
           = 140-Age x Body Weight (Kg) 
 Plasma Creatinine (mg/dl) x 72 
 (Multiply by 0.85 for women) 
 
 The patients who had GFR between 30 ml/mt and 90 
ml/mt are considered as Group I (Mild / moderate CRF). 
 
 The patients with GFR between 15 ml/mt and 29 ml/mt 
(severe CRF) are considered as Group II. 
 
 The patients with GFR below 15 ml/mt (ESRD) are 
considered as Group III. 
 
 The age and sex matched healthy controls are considered 
as Group IV. 
 
Consent : 
Informed consent was taken from all subjects participating in this 
study. 
 
Exclusion Criteria : 
The following patients were excluded from the study. 
• Patients with AV Fistula 
• Patients with diabetes mellitus 
• Patients with active or H/O recent infection during last 
three weeks. 
• Patients with H/O coronary artery disease and other 
cardiac disorders such as valvular heart disease, 
congenital heart disease etc. 
• Patients on haemodialysis. 
• Patients on treatment with erythropoietin. 
• Patients with H/O smoking and / or alcohol ingestion 
and all patients with poor echo window. 
 
All subjects underwent various investigations, haemoglobin, total 
and differential white cell electrolytes count, renal and liver function 
tests, urine analysis, lipid profile, Abdomen ultra sound, chest 
skiagram and 12 lead electro cardiography. 
 
METHOD 
 
Echocardiography 
Basic principles 
 It uses ultrasound to study the disposition and movement of 
valves and other structures within the heart. It depends on the 
reflection of ultrasound waves at interfaces between blood and more 
solid tissues. 
 
 In M mode echocardiography the ultrasound is focused into a 
narrow beam, and the output is a graph against time of the movement, 
relative to the chest wall of those structures through which the beam 
passes. Characteristic patterns of movement are produced in for 
example mitral stenosis and pericardial effusions are easily 
recognized. Accurate measurements can be made of cardiac 
dimensions. 
 
 In two dimensional real time echo cardiography, the ultrasound 
beam is swung rapidly back and front over an arc or sector and the 
resulting information synthesised into a two dimensional map or 
picture of the positon of the reflecting structures on a television screen. 
 
 The picture is the equivalent of a slice through the heart and the 
structures shown will depend on the position and orientation of the 
ultrasound crystal. 
 
 Because the beam oscillates very rapidly, the ultrasound image 
accurately produces the movement of structures in the living heart 
(hence real time). This type of echo cardiography is particularly good 
at detecting intracardiac masses such as Thrombi (or) tumors or 
endocarditic vegetations. It is also very useful in sorting out complex 
structural abnormalities in congenital heart disease. 
 
 Doppler cardiography depends on the fact that sound waves 
reflected from moving objects such as intra cardiac red blood cells, 
undergo a frequency shift. This can be used to detect the speed and 
direction of movement of the red cells and thus of the blood in the 
heart.  
 
Continuous wave Doppler uses a narrow beam of ultrasound in 
a way analogous to M mode echocardiography. 
 
Pulsed Doppler can sample blood movement at different depths 
beneath the transducer, and is frequently combined with 2D 
echocardiography so as to examine blood flow in relation to known 
intracardiac anatomy. Doppler cardiography is useful in detecting 
abnormal directions of blood flow eg. Aortic, mitral regurgitations and 
estimating pressure gradients which can be calculated from the 
maximum velocity of flow. Cardiac output can also be measured. 
 
Echocardiographic parameters assessed 
 All patients underwent two dimensional directed M mode 
echocardiography performed on Hewlett Packard SIM 7000, using 3.5 
MHZ transducer by cardiologists of this hospital. 
 
 The left ventricular ejection fraction (EF) and  fractional 
shortening (FS) were taken as measures of LV systolic function. EF 
was determined by measuring left ventricular volumes in apical 2 
chamber view. Left ventricular volumes were measured by Area – 
length method both in end diastole (LVVd) and in end systole (LVVs). 
 
 EF = LVVd – LVVs  
       LVVd 
 
 The mean EF in normal population is taken as 63.8 + 5.1 %. EF 
was considered decreased if it was < 50%. 
 
 Fractional shortening (FS) was determined by measuring left 
ventricular internal diameter in diastole (LVIDd) and left ventricular 
internal diameter in systole (LVIDs) by 2D directed M mode echo at the 
level of papillary muscle. 
 
 FS  = (LVIDd – LVIDs) x 100 
         LVIDd  
  Normal reference value in adults for FS is 35+8% FS of < 25% 
was taken as index of systolic dysfunction. 
 
 Diastolic function was determined by ratio of peak early diastole 
velocity (E)/peak atrial filling velocity (A) of LV i.e. (E/A) measured by 
spectral doppler LV inflow velocity with sample volume at the level of 
mitral valve. Normal value of doppler LV diastolic function index was 
taken as : Peak velocity E (m/sec) : 0.61 m/sec + 0.14, peak velocity A 
(m/sec) : 0.48 m/sec + 0.14 with a normal E/A ratio : 1.40+0.54. LV 
diastolic dysfunction was considered if E/A velocity was found            
to be < 1. 
 
Computer analysis of statistical data was done utilizing 
Epidemiological Information Package (EPI 6) developed by World Health 
Organisation. 
 
Range, Mean, Standard deviation and ‘p’ values were calculated 
using this software.Kruskal – Wallis test equivalent to Chi Square test  was 
used to find out the significance of relationship. 
  
 
 
 
 
 
 
 
 
 
RESULTS AND ANALYSIS  
 
RESULTS AND ANALYSIS 
 
Table 1 : Sex 
 
Group 
Gr. I 
(Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
Sex 
No. % No. % No. % No. % 
Male 21 70 20 66.7 19 63.3 21 70 
Female 9 30 10 33.3 11 36.7 9 30 
Total 30 100 30 100 30 100 30 100 
 
 
 A total number of 60 males and 30 females were selected for the 
study. 
 
 Both sexes were distributed in the same ratio in the study and 
the control population. 
 
 
Table 2 : Age 
 
Group 
Gr. I 
(Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
Age 
No. % No. % No. % No. % 
< 30 1 3.3 6 20 3 10 1 3.3 
31-40 17  13  14  15 50 
41-50 10  5  12  11  
> 50 2  6 20 1  3  
Total 30 100 30 100 30 100 30 100 
Range 30-55 28-58 29-52 28-58 
Mean 39.5 38.9 39.4 40.3 
S.D. 6.7 9.3 6.4 7.1 
 
'p'   = 0.1223 ( Not significant ) 
 
 Majority of the patients in both study and control group lies 
between 31 and 40 years. Almost same age group of patients were 
selected in both groups and there is no statistically significant 
difference in the age composition. 
Table 3 Weight 
 
Group Weight 
Gr. I 
(Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
Mean 61.1 62.0 56.0 59.2 
S.D. 6.1 5.0 6.8 5.4 
‘p’ 0.004 
 
 
 When compared to Group I patients, the average body weight is 
less in Group III patients. The difference is significant also. 
 
Table 4 Hb% 
 
Group Hb% 
Gr. I 
(Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
Mean 8.82 7.18 6.07 11.92 
S.D. 0.74 0.82 0.6 0.9 
‘p’ 0.0001 
 
 When compared to Group I patients, the average Hb level is less 
in Group II and Group III patients and it is statistically significant. As 
expected, the mean Hb level showed a progressive decline with the 
severity of renal failure. 
Table 5 Urea 
 
Group Urea 
Gr. I 
(Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
Mean 69.1 132.9 165.6 20.1 
S.D. 10.3 12.3 18.5 2.9 
‘p’ 0.0001 
 
   
Table 6 Creatinine 
 
Group Creatinine 
Gr. I 
(Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
Mean 2.33 4.66 7.0 0.7 
S.D. 0.43 0.53 0.96 0.22 
‘p’ 0.0001 
 
 As evident from Table 5 and Table 6, Blood urea and creatinine 
levels showed a progressive increase in their levels with increase in 
severity of renal failure which was statistically significant when 
compared to controls. ( 'p' < 0.05)  
 
Table 7 Echocardiographic parameters in 4 groups 
 
Group (in cm) 
Gr. I (Mild & 
Moderate CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
LVIDd 3.7+0.8 4.2+0.4 4.8+0.6 3.3+0.4 
LVIDs 2.6+0.7 2.9+0.6 3.3+0.4 2.2+0.3 
IVSd 1.3+0.3 1.4+0.2 1.6+0.4 1.1+0.2 
IVSs 1.4+0.4 1.5+0.2 1.8+0.5 1.3+0.1 
PWd 1.1+0.2 1.2+0.2 1.3+0.2 1.0+0.1 
LVVd (cubic 
ml) 
78.6+24.5 88.1+26.2 94+31.2 72.7+9.3 
LVVs(Cube 
ml) 
33.4+15.4 38.2+15.5 43.2+16.2 28.5+5.4 
 
 It is seen from the above Table, that the mean left ventricular 
internal diameter in diastolic ( LVIDd) and systolic (LVIDs) as well as 
the mean left ventricular volume in both systolic (LVVd) and diastolic 
(LVVd) were higher in the patients with mild/ moderate CRF and 
severe CRF groups than the control group. 
Table 8 : EF 
 
Group 
Gr. I (Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
EF 
No. % No. % No. % No. % 
Normal ( > 50%) 29 96.7 24 80 20 66.7 30 100 
Decreased (<50%) 1 3.3 6 20 10 33.3 - - 
Total 30 100 30 100 30 100 30 100 
Range 47.2-63.8 42.8-61.1 36.7-58.5 58.9-68.9 
Mean 59.5 56.3 51 63.1 
S.D. 3.0 5.9 8.6 3.6 
 
 Group I versus Group IV – p = 0.5 
 Group II versus Group IV – p = 0.01186 
 Group III versus Group IV – p = 0.0018 
 Group I versus Group III – p = 0.0076 
 Group II versus Group III – p = 0.3811 
 Group I versus Group II – p = 0.0514 
 
Table 8 shows indices of Left Ventricular (LV) systolic function in 
the four groups. As evident, LV Ejection Fraction showed a 
progressive decline with increase in severity of renal failure which was 
statistically significant   ( 'p'<0.05) when Group II and Group III patients 
are compared to controls. Further analysis showed that whereas in 
patients with mild / moderate CRF only 1 out of 30 (3.3%) patients 
showed low EF ( <50%), 6 out of 30 (20%) patients with severe CRF 
and 10 out of 30 (33.3%) with ESRD had evidence of low EF. 
Table 9 : Fractional Shortening (FS) 
 
Group 
Gr. I (Mild 
& Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
FS 
No. % No. % No. % No. % 
Normal ( > 25%) 29 96.7 17 56.7 14 46.7 30 100 
Decreased (<25%) 1 3.3 13 43.3 16 53.3 - - 
Total 30 100 30 100 30 100 30 100 
Range 24.9-36.1 22-34.2 18.4-30 29.9-37.1 
Mean 32.5 27.4 23.9 33.3 
S.D. 2.6 4.3 4.5 2.6 
 
 Group I versus Group IV – p = 0.5 
 Group II versus Group IV – p = 0.0002 
 Group III versus Group IV – p = 0.0001 
 Group I versus Group III – p = 0.0001 
 Group II versus Group III – p = 0.6053 
 Group I versus Group II – p = 0.0008 
 
As evident from Table 9, LV fractional shortening showed a 
progressive decline with increase in severity of renal failure. There is 
no statistically significant difference   ( 'p'>0.05) between  Group II and 
Group III.. Detailed analysis revealed that 1 out of 30 (3.3%) patients 
with mild / moderate CRF, 13 out of 30 (43.3%) patients with severe 
CRF and 16 out of 30 (53.3%) with ESRD had impaired fractional 
shortening (i.e., <  25%) 
 
Table 10 E/A Ratio 
 
Group 
Gr. I (Mild & 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
E/A Ratio 
No. % No. % No. % No. % 
Normal ( > 1) 24 80 18 60 11 36.7 30 100 
Decreased(<1) 6 20 11 36.7 17 56.7 - - 
Pseudonormalisation - - 1 3.3 2 6.7 - - 
Total 30 100 30 100 30 100 30 100 
Range 0.92-1.51 0.93-1.51 0.92-1.68 0.92-1.73 
Mean 1.115 1.101 1.115 1.483 
Standard deviation 0.17 0.18 0.25 0.12 
  
 Group I versus Group IV (Controls)– p = 0.0119 
 Group II versus Group IV – p = 0.1211 
 Group III versus Group IV – p = 0.0001 
 Group I versus Group III – p = 0.0017 
 Group II versus Group III – p = 0.1211 
 Group I versus Group II – p = 0.159 
 
Table 10 shows diastolic functions in the four groups. As 
evident, the mean E/A was significantly lower in patients with mild / 
moderate CRF, severe CRF and ESRD when compared to controls.  In 
mild / moderate CRF group 6 out of 30 patients (20%),in severe CRF 
11 out of 30 (36.7%) and in ESRD 17 out of 30 (56.7%) had diastolic 
dysfunction   (E/A <1) .Thus the Group III patients had significantly 
impaired diastolic function when compared to Group I patients. 
 
Table 11 Left Ventricular Hypertrophy (LVH) 
 
Group 
Gr. I 
(Mild 
Moderate 
CRP) 
Gr. II 
(Severe 
CRF) 
Gr. III 
(ESRD) 
Gr. IV 
(Controls) 
LVH 
No. % No. % No. % No. % 
ConcentricHypertrophy 4 13.3 9 30 8 26.7 - - 
Eccentric hypertrophy - - 3 10 6 20 - - 
Total 4 13.3 12 40 14 43.3 - - 
Range 118-238 145-275 147-324 110-217 
Mean 167.9 209 234.1 176.4 
Standard deviation 32.9 42.7 63.7 25.6 
 
 Group I versus Group IV (Controls) – p = 0.0562 
 Group II versus Group IV (Controls) – p = 0.0004 
 Group III versus Group IV (Controls) – p = 0.0002 
 Group I versus Group III – p   = 0.0219 
 Group II versus Group III – p   = 1.00 
 Group I versus Group II – p   = 0.041 
 
Table 11 shows the patients of LVH according to the severity of 
renal failure. The number of patients with concentric LVH among 
Group I patients was 4 (13.3%). Detailed analysis revealed that 4 out 
of 30 (13.3%) patients with mild / moderate CRF, 9 out of 30 (30 %) 
patients with severe CRF and 8 out of 30 (26.7%) with ESRD had 
concentric LVH whereas Nil patients in Group I, 3 out of 30 (10%) 
patients in Group II and 6 out of 30 (20%) in Group III had eccentric 
LVH (dilation of LV). 
 
Table 12 :  Hypertension and EF 
 
Group I Group II Group III Total RF EF 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
Normal 19 10 15 9 13 7 47 26 
Decreased 1 - 5 1 7 3 13 4 
 
p=0.0001 
 
 In normotensive CRF patients, Nil patients with mild to moderate 
CRF, 1 out of 10 (10 %) patients with severe CRF and 3 out of 10 
(30%) with ESRD had low Ejection Fraction (systolic dysfunction). 
Whereas in hypertensive CRF patients, 1 out of 20 (5%) patients with 
mild to moderate CRF, 5 out of 20 (25 %) patients with severe CRF 
and 7 out of 20 (35%) with ESRD had low Ejection Fraction. 
Table 13 : Hypertension and FS 
 
Group I Group II Group III Total RF FS 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
Normal 19 10 9 8 8 6 36 24 
Decreased 1 - 11 2 12 4 24 6 
 
p=0.0001 
 
In normotensive CRF patients, Nil patients with mild to moderate 
CRF, 2 out of 10 (20 %) patients with severe CRF and 4 out of 10 
(40%) with ESRD had low Fractional Shortening. Whereas in 
hypertensive CRF patients, 1 out of 20 (5%) patients with mild to 
moderate CRF, 11 out of 20 (55 %) patients with severe CRF and 12 
out of 20 (60%) with ESRD had low fractional shortening. 
 
 
Table 14 Hypertension and E/A 
 
Group I Group II Group III Total RF E/A Ratio 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
Normal 16 8 10 8 7 4 33 20 
Decreased 4 2 9 2 11 6 24 10 
Pseudo 
normalisation 
- - 1 - 2 - 3 - 
 
p=0.6703 
 
In normotensive CRF patients, 2 / 10(20%) patients with mild to 
moderate CRF, 2 / 10 (20 %) patients with severe CRF and 6  / 10        
( 60%) with ESRD had E/A slope < 1 ( diastolic dysfunction).  
 
In hypertensive CRF patients, 4 / 20 (20 %) patients with mild to 
moderate CRF, 10 / 20 (50 %) patients with severe CRF and 13 / 20 
(65%) with ESRD including patients with pseudonormal pattern had 
diastolic dysfunction. 
 
 
Table 15 Hypertension and LVH 
 
Group I Group II Group III Total RF LVH 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
A 
(with 
HT) 
B 
(Without 
HT) 
Positive 4 - 11 1 10 3 25 4 
Negative 16 10 9 9 10 7 35 26 
 
p=0.0001 
 
In normotensive CRF patients, nil patients with mild to moderate 
CRF, 1/10 (10%) patient with severe CRF and 3/10 (30%) patients with 
ESRD had LVH. 
 
In hypertensive CRF patients, 4/20 (20%) patients with mild to 
moderate CRF, 11/20 (55%) patients with severe CRF and 11/20 
(55%) patients with ESRD had LVH. 
 
  
 
 
 
 
 
 
 
 
 
DISCUSSION  
 
 
DISCUSSION 
 
 Premature cardiovascular disease is a significant cause of 
morbidity and mortality among patients with CRF. Various diagnostic 
modalities, both invasive and non invasive such as 
electrocardiography, echocardiography, and radionucleide scans are 
utilised for diagnosing left ventricular hypertrophy and dysfunction. 
Echocardiography provides an excellent non invasive method to 
delineate details of anatomy of cardiac cavity, wall dimensions, and 
wall movements. 
 
The study population consists of chronic renal failure patients 
admitted in this hospital for the period from March 2005 to February 
2006. They are basically divided into three groups according to 
Glomerular Filtration rate calculated by using one of the standard 
equations, Cockroft – Gault equation and each group consisted of 
thirty patients. In my study, of the thirty patients in each group, twenty 
patients were with hypertension and ten patients were without 
hypertension and not receiving any antihypertensive drugs. 
 
The patients who had GFR between 30 ml/mt and 90 ml/mt are 
considered as Group I (Mild / moderate CRF).The patients with GFR 
between 15 ml/mt and 29 ml/mt (severe CRF) are considered as 
Group II.The patients with GFR below 15 ml/mt (ESRD) are 
considered as Group III.The age and sex matched healthy controls are 
considered as Group IV. 
 
Comparative Analysis 
The study population in S. Agarwal et al study, consisted of 
three groups: group A (n=30) – age and  sex matched healthy controls; 
group B (n=30) – patients with mild to moderate CRF (S. creatinine 1.5 
– 6.0mg/dl): and group C (n=30) – patients with advanced CRF (S. 
creatinine > 6.0mg/dl). 
 
In a study conducted by R.V. Prasad et al, Kanpur 35 cases 
were divided in to three groups. Group A consisted of normal healthy 
controls. Group B and Group C were formed by hypertensive CRF 
patients and normotensive CRF patients respectively. 
 
Raj DS, D’ Mellos conducted a study in which the echo 
candiographic assessment was done in 38 chronic renal failure 
patients on conservative management, 35 patients on hemodialysis 
and 36 matched controls. 
 
In our study, the patients were grouped according to GFR 
whereas In S. Agarwal et al study, the patients were grouped on the 
basis of serum creatinine level. By using GFR, the patients can be 
appropriately classified into various degrees of renal failure rather than 
using only creatinine values. 
 
In our study, among 90 patients with various degrees of renal 
failure, 60 patients were male and 30 patients were females. So the 
male to female ratio is 2:1.  
 
In S. Agarwal et al study, among 60 patients with CRF, 34 
patients were male and 26 patients were females. Male patients are 
more prone to chronic renal failure than women. 
 
In Agarwal et al study, the age incidence was common among 
31-40 years. In our study also, the observation was similar.  
 
 In the western population, the age incidence is more in 51-60 
years (Barry N. Brenner). So in our Indian population, the younger age 
group are more affected. Because the bacterial infections like 
streptococcus and viral infection are more in our country than western 
country where diabetes mellitus and hypertension in old age group 
constitute the majority of chronic renal failure population. 
 
 The dry body weight decreases as the severity of renal failure 
increases because they suffer from chronic acidosis, malnutrition and 
anorexia. It has been observed in our study population. 
 
 As expected mean Hb level showed a progressive decline with 
the severity of renal failure. The results are similar to that of the study 
made by Dr. S. Agarwal, Dr. Rajpal, New Delhi 2003. 
 
The mean Hb values in our study are 8.8g/dl in Group1 
(mild/moderate CRF), 7.1g/dl in Group II (severe CRF), and 6.0g/dl in 
Group III (ESRD) patients. In Agarwal et al study, the mean Hb values 
were 13.2g/dl in mild/moderate CRF and 7.3g/dl in severe CRF. 
 
Mean values of Echocardiographic parameters in severe CRF 
 
 
Echo – parameters Agarwal et al study Present study 
LVIDd (cm) 4.7 4.8 
LVIDs (cm) 3.1 3.3 
LVVd (cubic ml) 92 94 
LVVs (cubic ml) 41 43.2 
 
 
 From this study, it is evident that as severity of renal failure 
increases, the mean left ventricular internal diameter (LVIDd) and 
systole (LVDs) as well as the mean left ventricular volume in both 
systole (LVVs) and diastole (LVVd) becomes more. 
 
Most of the studies made in Western population and Indian 
patients were based on serum creatinine levels in classifying the 
severity of CRF patients. (Greaves et al (1994), Raj et al (1997), Ayus 
et al (1981) and Dr. Agarwal and Rajpal (2003), New Delhi). In my 
study  the patients were classified on the basis of creatinine clearance 
which was calculated by using Cockroft Gault equation. 
 
 In the present study, the mean ejection fraction in patients 
with mild/moderate CRF and severe CRF groups showed a downward 
trend. Among patients in the mild / moderate CRF group only one 
patient had LVEF < 50%, while in advanced renal failure states (Group 
II and III), 16/60 (27%) patients had LVEF which was significantly 
different from controls, as well as mild/ moderate CRF population.  
 
In  S. Agarwal et al study, among patients in mild/moderate CRF 
only one patient had ejection fraction less than 50% (3.3%). while in 
severe CRF, 9/30 (30%) patients had low ejection fraction. The 
tendency of decrease in EF values with increase in severity  of renal 
failure  are similar in both study groups. 
 
 On analyzing the parameter, fractional shortening (FS), the 
percentage of Group I patients having FS less than 25% is 3.3% which 
is similar to that of patients with EF less than 50% whereas in Group II 
patients and III patients, more number of patients have low FS when 
compared to patients with low EF.  
 
 Group II patients with low EF and low FS are 20% and 43% 
respectively. Group III patients with low EF and low FS are 33% and 
53% respectively. 
 
 It is because when the ventricle is stressed by a haemodynamic 
overload, it first uses its compensatory mechanism to maintain normal 
mechanical performance and the ejection indices (eg. Ejection 
fraction) within normal limits. It is only when all the compensatory 
mechanisms in the form of operation of Frank Starling’s mechanism, 
development of hypertrophy, and endogenous adrenergic stimulation 
have been maximally used, there is decline in ejection phase indices. 
 
In Agarwal et al study, the number of patients showing low FS (< 
25%) were 7 patients (23%) in mild to moderate CRF and in severe 
CRF, there were 5 patients (16.6%). 
 
Among these two parameters (EF and FS), for assessing 
systolic function the ejection fraction is more reliable when compared 
to fractional shortening because FS assesses the status of basal 
chamber only; it may falsely be normal, depressed (or) increased in 
segmentally depressed left ventricle (Feigenbaum H ; Braunwald EEd 
Heart disease, 1992). 
 
Left ventricular diastolic dysfunction develops in three phases;  
1. Inversion of ratio of peak early to peak atrial velocity – 
curve with reduced early ventricular filling, due to reduced 
ventricular relaxation, 
2. Pseudonormalisation of E/A flow pattern, following 
increased atrial and ventricular filling pressures and 
decreased ventricular relaxation. 
3. Development of a restrictive pattern with various degrees 
of early atrial flow velocity involvement. 
 
Thus it may be difficult to interpret whether a normal E/A flow 
pattern is associated with normal heart function or might in fact be 
related to progressive diastolic heart dysfunction, with increased filling 
pressure, unless the pulmonary venous flow is analysed (Schroeder 
AP, Neilsen CB et al, 1997). 
 
In the present study, the mean E/A ratio in control group was 
1.48. It was 1.11 in mild/ moderate CRF patients, 1.101 in severe CRF 
and 1.115 in ESRD patients (the difference being statistically 
significant). The prevalence of diastolic dysfunction in the present 
study was found to be 20% (6 patients) in mild/moderate CRF, 36.7% 
(11 patients) in severe CRF group and 56.7% (17 patients) in ESRD 
group.  
 
The prevalence of systolic dysfunction as evidenced by low EF 
was found to be 3.3% (1 patient) in mild/ moderate CRF, 20% (6 
patients) in severe CRF and 33% (10 patients) in ESRD group.  
 
Thus in comparison to systolic function, diastolic function was 
deranged in more number of patients suggesting that diastolic function 
is first to appear in patients with chronic renal failure. 
 
All the patients with E/A ratio more than 1 were further studied 
by pulmonary venous flow pattern during echocardiography one 
patient from Group II and two patients from Group III with E/A ratio > 1 
were found to have large atrial reversal in pulmonary venous flow 
pattern (Pseudo normalization of E wave). 
 
In S. Agarwal et al study, the mean E/A ratio in control group 
was 1.4. It was 0.92 in mild/moderate CRF patients and 0.96 in severe 
CRF group (the difference being statistically significant). Similarly, 
Schroeder et al (1992) had found E/A ratio of velocity time indices to 
be 1.45 in patients with mild renal impairment as compared to 1.99 in 
controls. Also, in a study of ESRD patients by Virtanen et al (1998), 
mean E/A was 1.5 + 0.5. London et al (1993) reported a significant 
reduction in E/A ratio in haemodialysis patients as compared to 
controls. The prevalence of diastolic dysfunction in  S. Agarwal et al 
study was found to be 66.6% (20patients) in mild/moderate CRF group 
and 53.2% (16 patients) in severe CRF group. 
 
Among the various factors that constitute to diastolic and systolic 
dysfunction, uncontrolled hypertension and anaemia which are usually 
present in CRF, play a significant role. This has been observed in our 
study. 
Left ventricular hypertrophy (LVH) is the single strongest 
independent predictor of adverse cardiovascular events. LVH is a 
major echocardiographic finding in uremic patients. 
 
In the present study, we found that LVMI (LV Mass Index) 
showed a progressive rise with increase in severity of renal failure. 
This is in concordance with the study done by Greaves and co workers 
and Dr. S. Agarwal and co workers who also found a similar trend of 
LVMI in patients of CRF. 
 
A study done by Harnett et al revealed that a session of 
hemodialysis significantly decreased LVMI in CRF patients. 
 
In the present study, 4 patients (13%) in mild/ moderate CRF 
group, 12 patients (40%) in severe CRF and 13 patients (43%) in 
ESRD had LVH. 
 
It was also observed that concentric LVH is far more common 
than eccentric LVH (LV dilatation) in CRF population. 
 
As renal failure advances, the number of patients developing 
eccentric LVH increases as observed in our study. 
In P. Dangri and Agarwal et al study, 40% (12/30) of patients in 
mild/moderate CRF group and 96% (29/30) patients in severe CRF 
group had LVH. Concentric LVH was found in 11 out of 12 patients in 
mild/moderate CRF and 26 out of 29 patients in severe CRF. Eccentric 
LVH (LV dilatation) was found in one patient in mild/moderate CRF 
and 3 patients in severe CRF. In our study and P. Dangri et al study, 
concentric LVH was far more common than eccentric hypertrophy.  
 
In comparing various measurements in hypertensive CRF 
patients (20 patients in each group) with normotensive CRF patients 
(10 patients in each group) all the parameters were significantly 
deranged. 
 
LVH was observed in 13% of patients of normotensive CRF and 
it was seen in 43% of patients with hypertensive CRF. There was a 
direct correlation between LVMI and severity of CRF in both 
normotensive and hypertensive groups. 
 
The systolic dysfunction was observed in 13% of patients with 
normotensive CRF whereas in hypertensive CRF patients, the systolic 
dysfunction was observed in 21% of patients. 
 
The diastolic dysfunction was observed in 20% of patients with 
normotensive CRF whereas in hypertensive CRF patients, the diastolic 
dysfunction was noted in 40% of patients. So it can be understood that 
even in normotensive CRF patients, the diastolic dysfunction is more 
when compared to systolic dysfunction. 
 
In R.V. Prasad et al study, among normotensive CRF patients 
30% of patients had systolic dysfunction where as, among 
hypertensive CRF patients about 66% of patients were found  to have 
systolic dysfunction. (p < 0.05). The same study showed diastolic 
dysfunction in 86.6% in hypertensive CRF patients and 50% in 
normotensive CRF patients (p < 0.05) 
 
Pericardial effusion was present in 5 patients in Group II (16%) 
and 8 patients in Group III (26%). Most of the patients had mild to 
moderate pericardial effusion and none of them had cardiac 
tamponade. Pericardial thickening was present in 2 patients with 
ESRD (Group III). 
 
Pericardial involvement was found in 5.5% (5/90) of patients with 
CRF clinically but echo showed mild to moderate effusion in 14% 
(13/90) of patients. It directly correlated with severity of renal failure. 
In R.V. Prasad et al study pericardial involvement was found in 
8% of patients clinically but echo showed effusion in 36% (p < 0.05). 
 
Mitral regurgitation was observed in 3 (10%) patients in Group II 
and 5 patients (17%) in Group II . They had Grade I to Grade II MR. 
They were mainly observed in patients with eccentric hypertrophy (LV 
dilatation). 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION  
 
 
CONCLUSION 
 
The following conclusions were derived from this study. 
 
1. Majority of the patients in all groups of patients were in 
the age group of 31-40 years. 
2. The mean Hb level showed a progressive decline with 
the severity of renal failure. 
3. The average body weight is less in Group III (ESRD) 
patients. 
4. Blood urea and creatinine levels showed a progressive 
increase in their levels with increase in severity of renal 
failure. 
5. The echocardiographic parameters such as LVIDd, 
LVIDs and LVVd and LVVd were higher in the patients 
with mild / moderate CRF and severe CRF groups than 
the control group. 
6. 3.3% of patients with mild to moderate CRF, 20% of 
patients with severe CRF and 33.3% of patients with 
ESRD had systolic dysfunction. 
7. 20% of patients with mild to moderate CRF, 36% of 
patients with severe CRF and 56% of patients with 
ESRD had diastolic dysfunction. 
8. It can be understood that patients with chronic renal 
failure have higher prevalence of diastolic and systolic 
dysfunction and diastolic dysfunction appears to occur 
earlier than systolic dysfunction. 
9. 13.3% of patients with mild / moderate CRF, 40% of 
patients with severe CRF and 43% of patients had left 
ventricular hypertrophy. 
10. In comparison with normotensive CRF patients, all the 
echocardiographic parameters were significantly 
deranged in hypertensive CRF Patients. 
11. Clinically there was no valvular involvement but echo 
showed regurgitant lesions especially of  mitral valve in 
a significant number of cases. 
12. Calcification in the cardiac valves was not made out in 
any of the patients in our study and regional wall motion 
abnormality was not found in any of the patients and 
thrombus in the dilated ventricle was not found in any of 
the patients. 
 
Thus, echocardiography permits rapid and non invasive 
detection of cardiovascular complication in CRF, some of which 
remains unrecognized or even unsuspected during clinical 
examination, chest x-ray or ECG. 
  
 
 
 
 
 
 
 
 
 
SUMMARY 
SUMMARY 
 
 Patients with chronic kidney disease (CRF) most often present 
with non specific complaints (or) are asymptomatic and are suspected 
to have the disease because of abnormal blood or urine findings. So it 
is important to do complete evaluation for establishing the diagnosis, 
cause of CRF and various hemodynamic abnormalities associated with 
CRF.  
 
In particular, evaluation of cardio vascular risk factors is critical 
because of the high rate of cardio vascular complications in CRF. 
 
Echocardiography is one of the non invasive and sensitive tests 
for evaluating various cardiac changes in CRF patients at an early 
stage. 
 
 In the cardiovascular system, left ventricular hypertrophy 
and left ventricular diastolic and systolic dysfunction are the most 
frequent findings. Cardiac disease frequently predates the start of 
dialysis and cardiac dysfunction is the major impediment to 
rehabilitation. So echocardiography should be performed early in the 
course of CRF and may be valuable in the monitoring of therapy of 
these patients with modalities such as blood pressure control, 
correction of anemia, treatment of dyslipidemia and use of aspirin and 
statins in selected cases. 
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PROFORMA 
PROFORMA 
 
Name:        IP No: 
 
Age/Sex:       Body Weight:   (kg) 
 
Admitted for:         duration      Creatinine clearance     ml/mt/1.73m2 
 
Sweating of legs    Y/N     Past History 
 
Puffiness of face  Y/N     HT 
 
Scanty micturition  Y/N     DM 
 
Easy fatigability   Y/N     PT 
 
Anorexia                 Y/N     IHD 
 
Nausea, vomiting   Y/N     Others 
 
Breathlessness  Y/N 
 
Family History 
 
GENERAL EXAMINATION ANAEMIA +/- Pedaledeme +/- Dyspnoea +/-  
 
Vital signs  PR /Mt     BP /mm of Hg  RR /mt  Temp 
 
CVS 
 
RS 
 
ABD 
 
CNS 
 
INVESTIGATIONS 
 
 
 
Urine Alb          Sug            Dep 
 
Spot PCR  (Pr    : Cr ) 
Blood – Tc   DC-P:     L:              M:               E:             Hb% 
 
Blood   Sugar   Urea        Creatinine 
Serum    Calcium    Phosphorous    Electrolytes Na+  
K+  
C1- 
HCO3-) 
Lipid profile 
 
LFT 
 
 
ECG 
 
 
USG abd 
 
 
Echo 
 
Echocardiographic findings (Proforma) 
 
IVSd (cm) 
LVIDd (cm) 
PWd(cm) 
IVSs(cm) 
LVIDs (cm) 
PWa(cm) 
LVVs(Cubic ml) 
LVVd(Cubic ml) 
 
EF 
FS 
LVVM (g) 
 
Pericardial effusion 
Pericardial thickening 
DOPPLER STUDY 
 
1. Mitral Flow 
E 
A 
E/A Ratio 
MR- 
2. Pul.Venous flow 
 
 
3. Tricuspid Flow 
 
 
4. Other abnormalities 
 
Thrombus 
Pul HT 
 
Evidence of tamponade/ 
Constriction 
 
 
 
Impression: 
 
 
 
 
 
  
Sex 
60
30
Males Females
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRAPHS 
Mean age of the four groups
39.5
38.9
39.4
40.3
38
38.5
39
39.5
40
40.5
Group I (mild
&moderate CRF)
Group II (severe
CRF)
Group III(ESD) Controls
Group I (mild &moderate CRF) Group II (severe CRF) Group III(ESD) Controls
 
 
 
  
E/A Ratio for the four Groups
24
6
18
11
1
11
17
2
30
0
5
10
15
20
25
30
Group I (mild
&moderate CRF)
Group II (severe
CRF)
Group III(ESD) Controls
Normal Decrease d Pseudo normalisation
 
 
 
Mean LVH values in the four Groups
Group I (mild
&moderate CRF)
Group II (sev ere
CRF)
Group III(ESD) Controls
Mean LVH values
167.9
209
234.1
176.4
Mean LVH values
 
 
 
 
No. of patients with LVH
0
3
6
00
8
9
4
Group I (mild
&moderate CRF)
Group II (severe CRF) Group III(ESD) Controls
Concentric Hypertrophy Eccentric Hypertrophy
 
 
 
 Mean EF values in the four Groups
59.5
56.3
51
63.1
0
10
20
30
40
50
60
70
EF %
Group I (mild
&moderate CRF)
Group II (severe
CRF)
Group III(ESD) Controls
Group I (mild &moderate CRF) Group II (severe CRF)
Group III(ESD) Controls
 
 
 
Percentage of patients with normal and low EF values
96.7
3.3
80
20
66.7
33.3
100
0
0
10
20
30
40
50
60
70
80
90
100
EF %
Group I (mild
&moderate CRF)
Group II (severe
CRF)
Group III(ESD) Controls
Normal (>50%) Decreased (<50%)
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PICTURES 
 
 
 
 
 
 
Two-dimensional (2-D) Echo – Normal study 
 
 
 
 
 
 
 
Colour Doppler Echo – Normal study 
 
 
 
 
 
 
  
2D Echo - normal heart. Upper: Parasternal long axis view during diastole (left) and 
systole (right). Lower: Parasternal short axis view during diastole (left) and systole 
(right) 
 
 
 
 
 
 
 
  
 
 
CXR PA view showing Cardiomegaly with pulmonary congestion in 
a pt with CRF with CCF 
 
 
 
 
 
 
 
 
  
 
Chest X-ray PA View – Pericardial effusion & Bilateral pleural effusion 
in a case of severe CRF 
 
 
 
 
 
 
 
 
 
 
  
Echo picture of a case of ESRD – Severe cardiac dysfunction 
 
 
 
 
Left upper pulmonary vein pulsed wave Doppler flow pattern. 
There are three waves: systolic S wave, diastolic D wave, atrial reversal A 
wave. This image shows an abnormal diastolic dominant pattern. Normally the S 
wave is larger than the D wave. In severe MR there may be another wave of systolic 
flow reversal. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apical four-chamber view in a patient with a dilated cardiomyopathy 
 and severe mitral regurgitation in ESRD 
 
 
 
 
 
 
 
 
 
  
 
  
MASTER CHART 
 
S.No. Age Sex Group Wt.. HT Hb. Urea Creatinine Cr. Cl EF (%) FS(%) E A E/A LVH PE Others 
1 30 M I 58 + 10 60 1.6 55.4 57.4 33.4 0.57 0.5 1.14 173   
2 32 M I 60 + 11 68 2.1 42.9 61.7 36.1 0.61 0.54 1.13 178   
3 32 M I 62 + 9.8 62 1.5 62.1 60.8 35.4 0.57 0.54 1.06 167   
4 35 M I 65 + 9.9 80 2.1 45.1 56.5 29.6 0.73 0.51 1.43 168   
5 35 M I 64 + 8.8 90 2.3 40.6 59.8 30.3 0.81 0.62 1.31 174   
6 36 F I 56 + 8.5 96 2.8 30.6 62.7 35.9 0.69 0.53 1.3 140   
7 36 M I 64 + 8.7 66 1.5 61.6 61.6 34.6 0.59 0.54 1.09 171   
8 37 M I 68 + 9 70 2.9 33.5 58.4 30.4 0.72 0.69 1.04 169   
9 37 M I 69 + 8.8 76 3 32.9 59.9 30.8 0.73 0.79 0.92 237   
10 38 M I 70 + 10.1 64 2.7 36.7 62.8 35.2 0.81 0.79 1.03 230   
11 38 F I 68 + 8.4 67 2.6 31.5 60.3 34.9 0.79 0.78 1.01 120   
12 40 M I 69 + 8.2 80 3 31.9 47.2 24.9 0.56 0.55 1.02 232   
13 41 M I 69 + 9.1 72 2.8 33.9 56.8 29.7 0.61 0.66 0.92 170   
14 41 F I 68 + 8.6 60 2.2 36.1 62.1 34.8 0.74 0.53 1.4 134   
15 42 M I 67 + 8.5 96 2.3 39.6 60.7 33.4 0.75 0.63 1.19 178   
16 42 M I 58 + 8.8 64 2.4 32.9 57.5 32.8 0.83 0.9 0.92 180   
17 45 M I 55 + 9.2 58 2 36.3 57.8 31.7 0.6 0.55 1.09 165   
18 48 F I 59 + 8.1 62 2.2 30.2 58.2 32.3 0.54 0.53 1.02 124   
19 50 M I 68 + 8.2 70 2.8 30.4 59.1 33.1 0.79 0.85 0.93 173   
20 55 M I 62 + 8 64 2.1 34.9 60.2 33.6 0.59 0.54 1.09 238   
21 31 M I 50 - 9.4 62 2.1 36.1 58.4 30.4 0.73 0.51 1.43 164   
22 32 F I 54 - 8.4 68 2.3 30.9 58.3 29.9 0.81 0.79 1.03 118   
23 32 F I 51 - 8.2 67 2.1 30.9 63.8 35.8 0.56 0.55 1.02 139   
24 34 M I 52.5 - 9 69 2.4 32.2 62.7 35.1 0.72 0.69 1.04 175   
25 34 M I 56 - 7.9 68 2.8 30.4 61.8 34.9 0.82 0.87 0.94 171   
26 40 M I 59 - 7.8 70 2.9 30.3 60.9 33 0.79 0.85 0.93 169   
S.No. Age Sex Group Wt.. HT Hb. Urea Creatinine Cr. Cl EF (%) FS(%) E A E/A LVH PE Others 
27 46 F I 60 - 8.9 68 2.3 31.9 59.8 31.5 0.59 0.58 1.02 134   
28 46 F I 59 - 8.4 60 2.1 31.2 59.9 30.4 0.61 0.51 1.2 139   
29 48 F I 56 - 8.7 54 1.8 33.8 58.3 29.6 0.67 0.52 1.29 128   
30 51 M I 55 - 8.2 62 2.2 30.9 60.7 32.7 0.77 0.51 1.51 178   
31 28 M II 55 + 6.2 148 5 17.1 47.3 23.7 0.56 0.6 0.93 270   
32 29 M II 59 + 7.8 132 4.9 17.9 60.9 33.4 0.74 0.65 1.14 260   
33 29 F II 55 + 6.3 124 4.2 17.2 55.7 22.2 0.76 0.81 0.94 160 +  
34 30 M II 60 + 7.9 120 4.6 19.9 54.4 29.1 0.73 0.66 1.11 190   
35 30 M II 58.5 + 7.8 126 4.7 18.3 57.1 28.1 0.69 0.61 1.13 187   
36 31 M II 57.5 + 6.4 140 5.1 17.1 58.8 22.8 0.48 0.51 0.94 274   
37 31 M II 56.5 + 6.2 138 4.9 17.5 59 34.2 0.86 0.91 0.95 182   
38 32 M II 59 + 6.1 130 5.2 17.1 42.8 22.4 0.82 0.73 1.12 244  MR 
39 32 M II 56.5 + 6 140 5.1 16.6 44.9 23.6 0.5 0.53 0.94 256 + MR 
40 33 M II 60.5 + 6.4 142 5.2 17.3 60.7 22.7 0.74 0.78 0.95 187   
41 34 F II 56.5 + 6.7 100 4.1 17.2 59.8 23.1 0.74 0.67 1.1 227   
42 35 F II 57.5 + 6.2 124 4.1 17.4 60.1 23.5 0.83 0.79 1.05 235   
43 38 F II 58 + 7.8 98 3.2 21.8 61.1 33.7 0.6 0.57 1.05 154   
44 40 M II 64 + 8.1 140 4.2 21.2 60.7 31.2 0.73 0.61 1.2 183   
45 42 F II 63 + 6.8 140 4.3 16.9 60.2 22.1 0.81 0.87 0.93 160   
46 43 M II 67 + 8.2 130 4.7 19.2 59.9 30.7 0.85 0.56 1.52 274 +  
47 43 F II 68 + 7 150 5.1 15.3 47.5 23.1 0.86 0.92 0.93 260   
48 49 F II 69.5 + 6.6 140 5.6 13.3 45.4 22.9 0.8 0.75 1.07 253 +  
49 52 M II 70.5 + 7 136 5.5 15.7 55.1 29.7 0.84 0.9 0.93 275  MR 
50 58 M II 68 + 6.8 147 4.9 15.8 54.9 28.4 0.85 0.6 1.42 181   
51 30 M II 62 - 8.8 120 4.2 22.6 60.7 29 0.7 0.64 1.09 184   
52 31 F II 63 - 8.1 128 4.1 19.8 58.8 30.4 0.63 0.61 1.03 145   
53 32 M II 58 - 8.2 132 4.2 20.2 60.1 31.1 0.8 0.57 1.4 181   
54 38 M II 57 - 7.6 140 4.5 17.9 59.4 22.7 0.79 0.6 1.32 190 +  
55 40 F II 68 - 6.4 148 5.1 15.7 44.7 22 0.68 0.56 1.21 259   
S.No. Age Sex Group Wt.. HT Hb. Urea Creatinine Cr. Cl EF (%) FS(%) E A E/A LVH PE Others 
56 46 F II 62 - 6.8 128 4.2 16.4 58.3 32.1 0.74 0.79 0.94 157   
57 51 M II 66 - 7.2 139 5.4 15.1 58.9 33.3 0.69 0.72 0.96 189   
58 52 M II 64 - 7.8 140 4.8 16.2 60.8 30.4 0.7 0.59 1.19 187   
59 54 M II 68 - 8.2 138 4.4 18.4 61.1 29.4 0.84 0.56 1.5 181   
60 55 M II 71 - 8.1 128 4.3 19.5 59.9 30.6 0.63 0.61 1.03 184   
61 30 M III 62 + 6.8 154 6.6 14.3 36.7 18.4 1 0.8 1.25 300 + MR 
62 30 M III 58 + 6.4 148 6.2 14.2 58.5 20.5 1.01 0.6 1.68 310   
63 32 F III 54 + 7.1 142 5.8 11.8 57.3 30 0.59 0.62 0.95 250   
64 36 F III 41 + 6 148 6 8.4 52.2 19.5 0.97 0.61 1.59 164   
65 37 F III 47 + 5.8 158 6 9.5 54.4 20.3 0.99 0.62 1.6 160   
66 37 M III 51 + 6 160 6.8 10.7 56.8 29.4 0.85 0.9 0.94 200 +  
67 38 M III 48 + 5.8 172 7.1 9.5 57.1 20.6 0.94 1.02 0.92 310 + MR 
68 39 M III 64 + 4.8 178 8.2 10.9 58.4 29.4 0.89 0.6 1.48 320   
69 39 F III 62 + 4.9 182 8.1 9.1 36.7 18.5 0.73 0.61 1.2 250 + MR 
70 40 M III 53 + 5.9 142 6.2 11.8 57.2 21 0.72 0.78 0.92 190 +  
71 41 F III 55.5 + 5.8 164 7.2 9.1 39.4 20.9 0.81 0.86 0.94 256 +  
72 42 M III 58 + 5.9 168 7.4 10.6 37.2 20.1 0.65 0.59 1.1 194   
73 42 F III 59 + 6.2 144 6.1 11.1 53.4 27.8 0.84 0.9 0.93 156   
74 43 M III 64 + 6.1 142 6.2 13.9 55.7 29.3 0.79 0.64 1.23 198   
75 45 M III 67 + 6.4 140 6.4 13.8 57.4 28.1 0.83 0.6 1.38 324  MR 
76 45 M III 54 + 5.8 176 8.1 8.8 36.9 19 0.76 0.81 0.94 300   
77 47 F III 51 + 6.1 145 6.2 9.1 57.3 26.4 0.86 0.91 0.95 150   
78 48 M III 56 + 5.5 180 8.7 9.1 56.7 27.1 0.74 0.79 0.94 191  MR 
79 50 F III 48 + 5.7 184 8.2 6.2 41.3 19.3 0.85 0.91 0.93 264 +  
80 52 M III 50 + 5.2 190 8.8 6.9 40.7 18.9 0.89 0.95 0.94 316   
81 29 M III 57 - 6.1 154 6.9 12.7 58.5 28.4 1.01 0.99 1.02 197   
82 32 F III 54 - 6.4 160 6.1 11.2 57.9 28.6 0.97 0.59 1.64 147   
83 33 M III 64 - 6.8 170 7.1 13.3 58.3 28.1 0.71 0.76 0.93 195   
84 33 M III 57.5 - 7 156 6.9 12.3 57.8 27.9 0.98 0.83 1.18 189   
S.No. Age Sex Group Wt.. HT Hb. Urea Creatinine Cr. Cl EF (%) FS(%) E A E/A LVH PE Others 
85 34 F III 52 - 6.4 172 6.2 10.4 41.9 20.6 0.81 0.86 0.94 160 +  
86 36 F III 47 - 6.9 198 7.3 7.9 57.5 20.4 0.79 0.83 0.95 324   
87 37 M III 51 - 5.7 192 8.1 9.2 40.9 19.9 0.64 0.68 0.94 319   
88 42 M III 62 - 6.4 200 6.1 13.8 56.9 29.1 0.72 0.77 0.94 191   
89 44 M III 66 - 5.3 194 8.8 10.3 42.1 20.1 0.94 1.01 0.93 305   
90 50 M III 68 - 7 156 6.1 13.9 57.4 29.8 0.97 0.86 1.13 194   
91 30 M IV 59 - 12 18 0.4 100.2 60.6 34.9 0.64 0.49 1.31 169   
92 31 M IV 56 - 13 19 0.6 121.1 59.4 30.4 0.62 0.41 1.51 210   
93 31 F IV 58 - 11.8 18 0.4 124.4 58.9 29.9 0.68 0.44 1.55 110   
94 32 M IV 60 - 11.6 20 0.6 128.6 63.4 35.3 0.67 0.42 1.6 174   
95 32 M IV 60 - 12 18 0.4 112.5 67.9 37 0.73 0.43 1.7 185   
96 33 F IV 58 - 11.8 19 0.8 91.6 68.9 37.1 0.69 0.44 1.57 184   
97 33 M IV 62 - 13 18 0.6 131.6 62.4 32.2 0.64 0.5 1.28 217   
98 34 M IV 65 - 12 16 0.4 136.7 68.1 36.9 0.64 0.47 1.36 211   
99 35 F IV 62 - 11 19 0.6 128.1 61.5 31.4 0.74 0.48 1.54 113   
100 36 M IV 55 - 12 20 0.6 132.4 59.5 30.9 0.7 0.51 1.37 164   
101 36 M IV 56 - 13 18 0.6 101.1 64.3 33.6 0.69 0.45 1.53 189   
102 40 M IV 60 - 14 26 1 92.6 66.7 34.8 0.67 0.45 1.49 207   
103 41 M IV 64 - 12 22 1.1 125.7 68.1 36.5 0.6 0.49 1.22 196   
104 42 F IV 72 - 11 18 0.9 108.9 60.3 30.4 0.62 0.42 1.48 179   
105 43 M IV 59 - 11.2 24 0.8 99.4 62.1 31.7 0.71 0.48 1.48 190   
106 45 M IV 64 - 12 22 0.8 105.6 68.2 37.1 0.71 0.45 1.58 184   
107 50 M IV 62 - 11.8 18 0.6 129.2 59.1 29.9 0.73 0.46 1.59 167   
108 51 F IV 52 - 10.9 21 0.7 91.1 59 30.1 0.72 0.5 1.44 154   
109 51 M IV 68 - 12.8 26 1 105.1 60.1 31.3 0.67 0.44 1.52 176   
110 54 F IV 51 - 9.8 18 0.4 129.4 61.9 31.7 0.61 0.43 1.42 181   
111 35 M IV 55 - 12.8 22 0.6 133.7 64.5 34.8 0.73 0.49 1.49 169   
112 38 M IV 60 - 12.6 18 1 106.3 66.1 35.9 0.68 0.5 1.36 174   
113 39 F IV 52 - 11 26 0.8 103.3 68 37 0.69 0.47 1.47 149   
S.No. Age Sex Group Wt.. HT Hb. Urea Creatinine Cr. Cl EF (%) FS(%) E A E/A LVH PE Others 
114 40 M IV 64 - 12.8 24 0.6 126.9 58.9 30.4 0.7 0.45 1.56 179   
115 42 M IV 62 - 13 22 0.4 120.6 59 30.6 0.67 0.47 1.43 174   
116 43 F IV 48 - 10.8 18 0.8 91.6 60.4 31.5 0.62 0.49 1.27 186   
117 45 M IV 62 - 11 21 1.1 102.3 62.2 33.6 0.74 0.48 1.54 205   
118 48 M IV 59 - 12 16 0.8 94.2 64.7 33.4 0.73 0.42 1.74 199   
119 49 F IV 50 - 11 18 0.6 107.4 68.4 36.9 0.65 0.41 1.59 144   
120 50 M IV 62 - 12 21 1 96.9 60.9 32.2 0.69 0.45 1.53 153   
 
 
Group I Patients with creatinine clearance of  30 – 90ml/min/1.73m2 
 
Group II Patients with creatinine clearance of   15 – 29 ml/min/1.73m2 
 
Croup III Patients with creatinine clearance of   < 15 ml/min/1.73m2 
 
Group IV Controls 
 
HT  Hypertension       Cr. Cl.  Creatinine clearance 
 
EF  Ejection Fraction      FS  Fractional Shortening 
 
E  Early diastole velocity     A  Peak atrial filling velocity 
 
LVH  Left Ventricular Hypertrophy     PE  Pericardial effusion 
 
MR  Mitral regurgitation 
 
 
